Fig. 1 · Structure

Documents & Downloads

Avagacestat (BMS-708163)

Cat. No. A10157 CAS 1146699-66-2

Gamma-secretase inhibitor

BMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Avagacestat (BMS-708163) inhibits γ-secretase. Competition with a distinct photoaffinity derivative implicates presenilin-1: parent compound suppressed PS1-NTF labeling and blocked four active-site-directed probes. These experiments support a presenilin-associated mechanism; the proposed allosteric interpretation does not establish an atomic binding pose. [1]

APP-versus-Notch selectivity depends on the assay. Crump et al. reported a NICD/Aβ40 IC50 ratio of 3 in a cell-free assay. Gillman et al. reported a 193-fold ratio using cellular Aβ production and a separate Notch reporter assay. These results do not establish a universal Notch-sparing margin or explain the full discrepancy. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
γ secretase(Aβ42) 0.27 nM
γ secretase(Aβ40) 0.3 nM

Cellular Effect

Cell Line Activity Value Description Reference
CHO ED50 1.2 nM Inhibition of gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion after overnight incubation by ELISA [PMID: 23713656]
CHO ED50 71 nM Inhibition of gamma-secretase in CHO cells assessed expressing NotchdeltaE assessed as inhibition of notch cleavage after overnight incubation by luciferase reporter gene assay [PMID: 23713656]
CHO IC50 71 nM Inhibition of gamma-secretase in CHO cells after overnight incubation by luciferase reporter gene assay [PMID: 23312944]
HEK293 ED50 1.2 nM Inhibition of gamma-secretase in HEK293 cells after overnight incubation by Western blotting analysis [PMID: 23312944]
IMR-32 IC50 0.13 nM Inhibition of gamma-secretase in human IMR32 cell membrane using APP as substrate after 2 hrs by ELISA [PMID: 23312944]
IMR-32 IC50 1.5 nM Inhibition of gamma-secretase in human IMR32 cell membrane using Notch as substrate after 2 hrs by ELISA [PMID: 23312944]

In Vitro Studies

In H4-8Sw cells, avagacestat inhibited Aβ40 and Aβ42 formation with reported IC50 values of 0.30 ± 0.15 nM and 0.27 ± 0.12 nM, respectively (mean ± SD; n = 50 and 45 experiments). The Notch reporter comparison used another cell system and an overnight exposure. These IC50 values are assay endpoints, not recommended treatment concentrations. [2]

Cell-free APP and Notch cleavage inhibition

Biochemical assay · HeLa membrane γ-secretase with recombinant APP Sb4 (1 µM) or Notch1 N1-Sb1 (0.4 µM) substrate [1]

Avagacestat inhibited APP and Notch cleavage in a cell-free assay, with a reported NICD/Aβ40 IC50 ratio of 3. This contrasts with the larger reporter-based ratio reported by Gillman.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aβ40 generationIC50 0.26 ± 0.07 nM[1]
Aβ42 generationIC50 0.35 ± 0.3 nM[1]
NICD generationIC50 0.84 ± 0.3 nM[1]
NICD IC50/Aβ40 IC50Selectivity ratio 3[1]

Literature-Reported Treatment Conditions

Exposure duration
2.5 h
Method
Cleavage-product detection by AlphaLISA in 0.25% CHAPSO
Reported limits
Exact inhibitor concentration series, vehicle fraction, replicate number and meaning of ± are not specified in Table 1 or the retrieved assay paragraph.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708,163

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Table 1, cell-free rows; paragraph preceding/following Table 1; SI S4–S5, In vitro cell-free assay

Aβ40 generation: Cell-free cleavage assay; ± reproduced without assigning SD/SEM or n. — Table 1, cell-free BMS-708,163 row; SI S4–S5

Aβ42 generation: Cell-free cleavage assay; ± reproduced without assigning SD/SEM or n. — Table 1, cell-free BMS-708,163 row; SI S4–S5

NICD generation: Cell-free cleavage assay; ± reproduced without assigning SD/SEM or n. — Table 1, cell-free BMS-708,163 row; SI S4–S5

NICD IC50/Aβ40 IC50: Reported ratio; not a treatment concentration. — Table 1, cell-free BMS-708,163 row

Probe competition implicates presenilin-1

Biochemical assay · HeLa membranes; HEK293-Swe and PS1ΔE9 membranes provide target-identity control [1]

Parent compound competed labeling by its distinct 163-BPyne derivative and blocked four active-site-directed probes. Results support a presenilin-associated γ-secretase inhibitory mechanism; an allosteric interpretation was proposed, without a resolved binding structure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
163-BPyne labeling challenged by parent BMS-708,163Qualitative competition Parent suppressed specific PS1-NTF labeling[1]
Comparator competition with 163-BPyneQualitative comparator response Pan-GSIs blocked labeling; L-685,458 partially blocked it; E2012 and GSM-1 did not block it at 25 µM[1]
PS1-NTF labeling by four active-site-directed probesQualitative competition BMS-708,163 at 2 µM blocked labeling by L646, L505, GY4 and JC8[1]

Literature-Reported Treatment Conditions

Treatment concentration
Parent 1 µM for 163-BPyne competition; parent 2 µM for active-site probe competition; 163-BPyne 20 nM in HeLa membranes
Exposure duration
1 h incubation at 37 °C before crosslinking for 163-BPyne experiments
Method
Photoaffinity labeling followed by fluorescence/Coomassie or biotin enrichment and PS1-NTF immunoblot
Vehicle
DMSO comparator shown in Figure 2b; final incubation fraction not specified
Reported limits
No quantitative binding affinity or replicate count supplied for Figure 2. Photoprobe is a modified compound, not the catalog material.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708,163

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Figure 2a–d and associated target-identification/competition paragraphs; SI S5–S8, labeling methods and Supplementary Figures 1–2

163-BPyne labeling challenged by parent BMS-708,163: DMSO comparator, Coomassie loading control, subunit blots and PS1ΔE9 mobility-shift control support assignment. — Figure 2a,b; SI Supplementary Figures 1–2

Comparator competition with 163-BPyne: GSI comparators at 1 µM; GSM comparators at 25 µM. — Figure 2b and associated competition paragraph

PS1-NTF labeling by four active-site-directed probes: Parent-present versus parent-absent immunoblots; no percentage estimated from bands. — Figure 2c,d and caption

Cellular Aβ inhibition and reporter-based Notch comparison

Cell-based study · H4-8Sw neuroglioma cells expressing APP751 Swedish mutant for Aβ; HeLa cells expressing mouse Notch1-ΔE and CBF1-luciferase for Notch signaling [2]

Compound 4 inhibited cellular Aβ40 and Aβ42. A separate Notch reporter assay yielded a reported 193-fold Notch/APP ratio (95% CI 163–232); this is a comparison across assay systems, not universal substrate selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aβ40 formationIC50 0.30 ± 0.15 nM (mean ± SD, n = 50)[2]
Aβ42 formationIC50 0.27 ± 0.12 nM (mean ± SD, n = 45)[2]
Mouse Notch1-ΔE/CBF1 reporter signalingIC50 58 ± 23 nM (mean ± SD, n = 58)[2]
Notch reporter IC50/Aβ40 cellular IC50Selectivity ratio 193-fold (95% CI = 163–232)[2]

Literature-Reported Treatment Conditions

Exposure duration
Aβ: 19 h at 37 °C; Notch reporter: overnight at 37 °C
Method
Aβ immunoassay and CBF1-luciferase concentration-response fitting
Vehicle
Serially diluted DMSO stocks; Notch assay final DMSO 0.1%; APP assay 0.1 µL stock added to 30 µL cells
Reported limits
Exact compound series and untreated normalization details are not specified in the cited protocol. Reported n values refer to multiple experiments, not cell counts.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: 4

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Main paragraphs beginning Compound 4 potently inhibited and In addition to APP processing; SI Biological Protocols: Inhibition of Aβ formation / Inhibition of Notch signaling in cultured cells

Aβ40 formation: Concentration-response assay; n represents reported experiments. — Main cellular potency and Notch comparison paragraphs; SI Biological Protocols

Aβ42 formation: Concentration-response assay; n represents reported experiments. — Main cellular potency and Notch comparison paragraphs; SI Biological Protocols

Mouse Notch1-ΔE/CBF1 reporter signaling: Concentration-response assay; n represents reported experiments. — Main cellular potency and Notch comparison paragraphs; SI Biological Protocols

Notch reporter IC50/Aβ40 cellular IC50: Reported cross-assay ratio. — Main paragraph reporting Notch/APP selectivity

In Vivo Studies

Single oral doses of 10 or 100 mg/kg reduced plasma and brain Aβ40 throughout the 24 h observation interval in female rats. At 1 mg/kg, plasma Aβ increased and brain Aβ40 lowering lasted 8 h. The low-dose response limits a simple assumption that all exposures lower every Aβ compartment. [2]

In 5.5-month-old Tg2576 mice, a 1 mg/kg dose improved Y-maze alternation acutely, but the benefit was absent after 8 days. In 3-month-old Tg2576 mice, 10 mg/kg daily impaired alternation on day 8, with no significant acute effect. Hippocampal β-CTF increased; its causal role in the behavioral changes remains unproven. [3]

Single-dose plasma and brain Aβ40 time course in rats

Animal study · Female Sprague-Dawley rats; n = 3 animals per time point [2]

Oral avagacestat lowered brain and plasma Aβ40 at higher doses. At 1 mg/kg, plasma Aβ increased while brain Aβ40 lowering was transient. These are biomarker outcomes, not evidence of cognitive benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma and brain Aβ40 relative to vehicleTime-course direction Mean ± SEM; n = 3 animals per time point; dose-dependent lowering with low-dose plasma increase[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
24 h pharmacodynamic time course after one dose
Vehicle
99% PEG-400, 1% Tween-80; oral gavage at 4 mL/kg in SI rat protocol
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Low-dose avagacestat
1 mg/kg
Vehicle-dosed rats; Figure 2 shows time-matched vehicle series.Plasma Aβ increased; brain Aβ40 significantly lowered for 8 h according to text.[2]
Avagacestat 10 mg/kg
10 mg/kg
Vehicle-dosed rats; Figure 2 shows time-matched vehicle series.Plasma and brain Aβ40 significantly reduced throughout the 24 h dosing interval according to text.[2]
Avagacestat 100 mg/kg
100 mg/kg
Vehicle-dosed rats; Figure 2 shows time-matched vehicle series.Plasma and brain Aβ40 significantly reduced throughout the 24 h dosing interval according to text.[2]
Low-dose avagacestat
Model: Female Sprague-Dawley rats; n = 3 animals per time point
Reported limits: No exact outcome means estimated from plotted bars/curves.
Avagacestat 10 mg/kg
Model: Female Sprague-Dawley rats; n = 3 animals per time point
Reported limits: No exact outcome means estimated from plotted bars/curves.
Avagacestat 100 mg/kg
Model: Female Sprague-Dawley rats; n = 3 animals per time point
Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: 4

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation

Plasma and brain Aβ40 relative to vehicle: Antibody immunoassays; exact point estimates not transcribed from curves. — Figure 2A,B, caption and immediately preceding paragraph; SI rat assays/validation

Low-dose avagacestat · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation

Avagacestat 10 mg/kg · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation

Avagacestat 100 mg/kg · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation

Acute benefit did not persist after repeated dosing in older Tg2576 mice

Animal study · Female 5.5-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group [3]

A 1 mg/kg acute dose improved Y-maze alternation, but this benefit was absent on day 8. Hippocampal β-CTF increased without measurable Aβ40/Aβ42 lowering up to 10 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Y-maze spontaneous alternationBehavioral effect At 1 mg/kg, day-1 improvement was significant (p < 0.05); no significant benefit on day 8.[3]
Hippocampal Aβ40, Aβ42 and β-CTFELISA direction β-CTF increased; no Aβ lowering up to 10 mg/kg[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
8 days; Y-maze tested 3 h after dosing on days 1 and 8
Vehicle
0.5% methyl cellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Avagacestat dose series
0.1, 0.3, 1, 3 and 10 mg/kg
Vehicle-treated Tg2576 mice; vehicle-treated WT mice establish baseline cognitive status. LY450139 and GSM-2 are parallel comparators in Experiment 1; LY450139 in Experiment 3.At 1 mg/kg, day-1 improvement was significant (p < 0.05); no significant benefit on day 8. Day-8 β-CTF rose 11–50% at 1–10 mg/kg (p < 0.01 at 3–10 mg/kg); neither Aβ40 nor Aβ42 decreased up to 10 mg/kg.[3]
Avagacestat dose series
Model: Female 5.5-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group
Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708163

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Results Experiment 1; Figure 3A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis

Y-maze spontaneous alternation: Mean ± SEM, n = 7 or 8. Dunnett multiple-comparison test against vehicle; WT/Tg comparisons use Student t test. — Results Experiment 1; Figure 3A,B and caption; Methods Y-maze/Statistical analysis

Hippocampal Aβ40, Aβ42 and β-CTF: Measured after Y-maze; association does not demonstrate β-CTF-mediated causation. — Results Experiment 1; Figure 3A,B and caption; Methods Quantitation of hippocampal Aβ and β-CTF levels

Avagacestat dose series · Results Experiment 1; Figure 3A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis

Repeated dosing impaired Y-maze performance in younger Tg2576 mice

Animal study · Female 3-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group [3]

Avagacestat did not significantly alter alternation acutely but reduced it after 8 days at 10 mg/kg. Increased hippocampal β-CTF accompanied the response; causation was not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Y-maze spontaneous alternationBehavioral effect No significant acute effect; day-8 impairment at 10 mg/kg (p < 0.05)[3]
Hippocampal Aβ40, Aβ42 and β-CTFELISA direction β-CTF increased; Aβ lowered at 10 mg/kg[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
8 days; Y-maze tested 3 h after dosing on days 1 and 8
Vehicle
0.5% methyl cellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Avagacestat dose series
1, 3 and 10 mg/kg
Vehicle-treated Tg2576 mice; vehicle-treated WT mice establish baseline cognitive status. LY450139 and GSM-2 are parallel comparators in Experiment 1; LY450139 in Experiment 3.No significant day-1 alternation effect. Day-8 alternation reduced at 10 mg/kg (p < 0.05). β-CTF increased 18–63% at 3–10 mg/kg; Aβ levels were lowered at 10 mg/kg.[3]
Avagacestat dose series
Model: Female 3-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group
Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations

Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708163

Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.

Results Experiment 3; Figure 5A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis

Y-maze spontaneous alternation: Mean ± SEM, n = 7 or 8. Dunnett multiple-comparison test against vehicle; WT/Tg comparisons use Student t test. — Results Experiment 3; Figure 5A,B and caption; Methods Y-maze/Statistical analysis

Hippocampal Aβ40, Aβ42 and β-CTF: Measured after Y-maze; association does not demonstrate β-CTF-mediated causation. — Results Experiment 3; Figure 5A,B and caption; Methods Quantitation of hippocampal Aβ and β-CTF levels

Avagacestat dose series · Results Experiment 3; Figure 5A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1146699-66-2
Applications Gamma-secretase inhibitor
Formula C20H17ClF4N4O4S
Molecular Weight 520.8
Synonyms BMS-708163
SMILES
C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (172.78 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Christina J. Crump, Suita V. Castro, Feng Wang, et al. BMS-708,163 Targets Presenilin and Lacks Notch-Sparing Activity Biochemistry (2012). PMID: 22931393 DOI: 10.1021/bi301137h Source material
  2. [2] Kevin W. Gillman, John E. Starrett Jr., Michael F. Parker, et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor ACS Medicinal Chemistry Letters (2010). PMID: 24900185 DOI: 10.1021/ml1000239 Source material
  3. [3] Yasuyuki Mitani, Junko Yarimizu, Kyoko Saita, et al. Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice The Journal of Neuroscience (2012). PMID: 22323718 DOI: 10.1523/jneurosci.4264-11.2012 Source material

Added to your cart

View Cart Checkout
Loading...